Fortress Biotech (FBIO) Competitors $1.97 +0.03 (+1.55%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.97 0.00 (0.00%) As of 07/25/2025 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FBIO vs. AGEN, IRWD, SGMO, ACHV, DOMH, SABS, CRIS, BOLT, AMGN, and GILDShould you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Agenus (AGEN), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), Dominari (DOMH), SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), and Gilead Sciences (GILD). These companies are all part of the "biotechnology" industry. Fortress Biotech vs. Its Competitors Agenus Ironwood Pharmaceuticals Sangamo Therapeutics Achieve Life Sciences Dominari SAB Biotherapeutics Curis Bolt Biotherapeutics Amgen Gilead Sciences Fortress Biotech (NASDAQ:FBIO) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Which has preferable earnings & valuation, FBIO or AGEN? Fortress Biotech has higher earnings, but lower revenue than Agenus. Fortress Biotech is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFortress Biotech$57.67M1.01-$46M-$2.23-0.88Agenus$103.46M1.58-$227.21M-$8.67-0.69 Do insiders & institutionals believe in FBIO or AGEN? 96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 27.9% of Fortress Biotech shares are owned by company insiders. Comparatively, 5.5% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor FBIO or AGEN? In the previous week, Agenus had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Agenus and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.94 beat Agenus' score of 0.62 indicating that Fortress Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agenus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer FBIO or AGEN? Fortress Biotech presently has a consensus target price of $21.00, indicating a potential upside of 965.99%. Agenus has a consensus target price of $16.33, indicating a potential upside of 174.05%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Agenus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Agenus 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is FBIO or AGEN more profitable? Fortress Biotech has a net margin of -71.24% compared to Agenus' net margin of -196.12%. Agenus' return on equity of 0.00% beat Fortress Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Fortress Biotech-71.24% -4,712.53% -27.67% Agenus -196.12%N/A -82.33% Which has more risk and volatility, FBIO or AGEN? Fortress Biotech has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. SummaryFortress Biotech beats Agenus on 10 of the 15 factors compared between the two stocks. Get Fortress Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBIO vs. The Competition Export to ExcelMetricFortress BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.37M$3.05B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-0.8821.3228.4120.08Price / Sales1.01285.38432.3189.32Price / CashN/A42.7636.2258.56Price / Book-32.838.378.675.88Net Income-$46M-$55.19M$3.25B$258.89M7 Day Performance1.03%5.86%4.25%3.71%1 Month Performance6.49%17.29%10.51%11.72%1 Year Performance-12.44%4.39%35.68%18.01% Fortress Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBIOFortress Biotech2.5057 of 5 stars$1.97+1.5%$21.00+966.0%-24.2%$57.37M$57.67M-0.88170AGENAgenus4.219 of 5 stars$6.09-1.0%$16.33+168.2%-0.1%$168.61M$103.46M-0.70440Positive NewsIRWDIronwood Pharmaceuticals4.3673 of 5 stars$0.76-0.5%$4.78+526.6%-88.0%$124.20M$351.41M-3.82220Positive NewsSGMOSangamo Therapeutics2.3932 of 5 stars$0.49-3.1%$4.50+809.8%-12.9%$118.96M$57.80M0.00480Positive NewsACHVAchieve Life Sciences2.8069 of 5 stars$2.66-0.7%$14.33+438.8%-45.2%$92.96MN/A-1.9920High Trading VolumeDOMHDominari1.0874 of 5 stars$5.22-3.2%N/A+181.1%$78.93M$18.15M-1.164SABSSAB Biotherapeutics3.6868 of 5 stars$2.70+5.1%$13.25+390.7%-7.6%$23.87M$1.32M-0.73140News CoverageAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeCRISCuris2.5717 of 5 stars$1.74-3.3%$17.00+877.0%-69.4%$18.83M$10.91M-0.2860Positive NewsUpcoming EarningsBOLTBolt Biotherapeutics2.7101 of 5 stars$5.74+3.8%$50.00+771.1%-57.1%$10.60M$7.69M-0.1790Positive NewsHigh Trading VolumeAMGNAmgen4.3994 of 5 stars$295.87+0.4%$308.32+4.2%-8.3%$158.49B$33.42B27.0028,000Positive NewsAnalyst ForecastGILDGilead Sciences4.886 of 5 stars$108.28+0.1%$111.38+2.9%+51.9%$134.62B$28.75B13.9817,600Trending NewsAnalyst Upgrade Related Companies and Tools Related Companies AGEN Alternatives IRWD Alternatives SGMO Alternatives ACHV Alternatives DOMH Alternatives SABS Alternatives CRIS Alternatives BOLT Alternatives AMGN Alternatives GILD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FBIO) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fortress Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
